Characterization of tumour heterogeneity through segmentation-free representation learning on multiplexed imaging data
2025 · Nature Biomedical Engineering · 4 citations
https://doi.org/10.1038/s41551-025-01348-1
Y
Y. Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
139
Papers
283
Citations
8
h-index
4
i10-index
Y. Liu is an academic researcher from Xinjiang Medical University. The author has contributed to research in topics: Computational Drug Discovery Methods & Breast Cancer Treatment Studies & Cancer Genomics and Diagnostics. The author has an h-index of 8, co-authored 119 publications.
ORCID: 0009-0007-6120-8023Papers by this author
works822P Preliminary results from a phase Ib study of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
2024 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2024.08.873
Supplementary Table S1 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRAS<sup>G12C</sup> Inhibitor Efficacy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25541567.v1
Supplementary Figures 1-7 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRAS<sup>G12C</sup> Inhibitor Efficacy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25541570.v1
Supplementary Figure Legend from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRAS<sup>G12C</sup> Inhibitor Efficacy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25541573
Supplementary Table S3 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRAS<sup>G12C</sup> Inhibitor Efficacy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25541552
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat